ClinPGx Blog (Page 16)

Sign in Subscribe

More issues

PharmGKB data used to establish a minimum genetic testing panel for psychiatry

The lack of standardization of which genes or alleles should be included in pharmacogenetic testing panels is a major barrier to the full implementation of pharmacogenomics in the clinic. In an effort to help clinicians select an appropriate pharmacogenetic test, Dr. Chad Bousman and Dr. Abdullah Al Maruf of the

DPYD genotyping implementation study published

In a journal article published online last week in The Lancet Oncology, Henricks et al. reported that DPYD genotype-based dose reductions of fluorouracil and capecitabine in cancer patients resulted in improved safety outcomes and was feasible in clinical practice. The authors prospectively genotyped four DPYD variants: rs3918290 (1905+1G>

PharmGKB oxycodone pathway published in Pharmacogenetics and Genomics

The PharmGKB Oxycodone Pathway, Pharmacokinetics is featured on the cover of the October 2018 issue of Pharmacogenetics and Genomics. Oxycodone is an opioid analgesic metabolized by CYP2D6 and CYP3A4/5 to a number of metabolites, including oxymorphone which itself can be used as an analgesic.The pathway was produced by

CPIC grant awarded

The co-PIs of the Clinical Pharmacogenetics Implementation Consortium (CPIC), Drs. Mary Relling of St. Jude Children's Research Hospital (SJCRH) and Teri Klein of Stanford University, will receive $5 million over the next 5 years from the National Institutes of Health (NIH) to continue and expand the project. CPIC

Curators' Favorite Papers

An article in Pharmacogenomics Journal puts the spotlight on the need to continue look for candidate genes and variants in many populations even when it seems as though current candidates explain a large amount of variability. [PMID: 30100615] identifies new candidate genes and variants that are important when the most

PharmGKB Clozapine PK Pathway appears on the cover of Pharmacogenetics and Genomics

The Clozapine Pharmacokinetics Pathway is featured on the cover of September 2018 volume 28 issue 9 of Pharmacogenetics and Genomics. This pathway shows the candidate genes involved in the metabolism of the antipsychotic drug clozapine and was developed by curator Dr Caroline F. Thorn with Professor Daniel Mueller of the

CYP2D6 genotype to phenotype standardization project - seeking feedback

The assignment of the CYP2D6 metabolizer phenotype based on a subject's genotype is an important aspect of clinical implementation of pharmacogenetics knowledge. Especially for CYP2D6, the genotype-inferred phenotypes vary across laboratories and guidelines. The goal of the CYP2D6 genotype to phenotype standardization project is to harmonize this translation.

NHGRI/NCI survey on genomics education

The National Human Genome Research Institute (NHGRI), who are supportive of PharmGKB and CPIC, have teamed up with the National Cancer Institute (NCI) to survey research and healthcare professionals about genomics education. The results of this survey will help to determine the resource and training priorities for future genomics education.

PharmGKB Demo at U-PGx Summer School

PharmGKB recently held a demonstration of the PharmGKB website as part of the U-PGx Summer School in Bonn, Germany. Scientists, clinicians and pharmacists attending the summer school heard from Dr. Rachel Huddart, one of our Scientific Curators, and were introduced to the various types of information found on the PharmGKB

Changes to the PharmGKB data licensing, downloads and user accounts

PharmGKB is changing its licensing policy in order to simplify access to files containing annotations and relationships. All of PharmGKB, including these files, are now licensed under the Creative Commons Attribution-ShareAlike 4.0 International License. Users who download or use PharmGKB annotations, knowledge, files, images or screen shots agree to